Our scoping review particularly explores the use of glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs), medications originally intended for treating type 2 diabetes, as possible therapies for PCOS management. Here, GLP1R is linked to polycystic ovary syndrome.